Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma
Interventions: DRUG: Dinaciclib|DRUG: Epirubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)